| Burhan, Erlina |
NCT05118490: Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients |
|
|
| Recruiting | 4 | 1000 | RoW | Daily rifapentine and isoniazid for 4 weeks, Weekly rifapentine and isoniazid for 12 weeks | The Aurum Institute NPC, Johns Hopkins University | HIV Seropositivity, Tuberculosis, Household Contact | 10/24 | 12/24 | | |
NCT04847102: A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above |
|
|
| Recruiting | 3 | 28000 | RoW | SARS-CoV-2 mRNA Vaccine, Placebo | Walvax Biotechnology Co., Ltd., Abogen Biosciences Co. Ltd., Yuxi Walvax Biotechnology Co., Ltd. | COVID-19, SARS-CoV-2 | 11/21 | 05/23 | | |
| Terminated | 2/3 | 369 | Europe, RoW | BDB-001 Injection, Conventional treatment | Staidson (Beijing) Biopharmaceuticals Co., Ltd, Beijing Defengrui Biotechnology Co. Ltd | COVID-19 Pneumonia | 03/24 | 03/24 | | |
NCT04457609: Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients |
|
|
| Recruiting | 1 | 40 | RoW | Oseltamivir, Azithromycin, Umbilical Cord Mesenchymal Stem Cells | Indonesia University | COVID, Pulmonary Infection, Sars-CoV2 | 08/20 | 09/20 | | |
| Not yet recruiting | 1 | 36 | NA | Tuberculosis (TB) vaccine (Ad5-105K), Placebo, Ad5-105K | CanSino Biologics Inc., PT Etana Biotechnologies Indonesia | Tuberculosis | 08/25 | 08/25 | | |
